LungQ
AI-powered modular technology platform for comprehensive thoracic CT image analysis and lung disease quantification
Platform · Cloud SaaSCompany source
Company profile
About Thirona
Thirona is a medical imaging AI company specializing in advanced lung image analysis through its flagship LungQ® technology platform. The company provides AI-powered quantitative CT analysis solutions that support pharmaceutical drug development and minimally invasive pulmonary interventions. LungQ® offers modular deep-learning algorithms for comprehensive assessment of lung anatomy and diseased lung regions, including parenchymal analysis, bronchial analysis, and vascular analysis. The platform delivers precise segmentation and quantification capabilities extending from lobe-to-subsegmental level, enabling sensitive detection of disease progression and treatment response. Thirona's technology is extensively validated across major lung diseases including COPD, severe asthma, cystic fibrosis, and bronchiectasis disease. The company serves pharmaceutical companies, medical device manufacturers, clinical research organizations, and healthcare providers. With over 1 million images analyzed and partnerships with 100+ hospitals worldwide, Thirona combines strong scientific expertise in thoracic imaging with rigorous validation and regulatory compliance. The company's solutions enable quantitative assessment for imaging-based respiratory clinical trials and support bronchoscopic procedure planning and surgical decision-making through advanced anatomical intelligence.
Company description Thirona official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Thirona?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Bronchiectasis Disease
- COPD
- Cystic Fibrosis
- Interstitial Lung Disease (ILD)
- Lung Cancer
- Pulmonary Hypertension
- Pulmonary Vascular Diseases
- Severe Asthma
Who it serves
- Academic Medical Centers
- Clinical Research Organizations
- Healthcare Providers
- Medical Device Companies
- Pharmaceutical Companies
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · Multi-country (12 countries in ENRICH project) · Netherlands
Company sourceOfficial website
Company milestones
Platform expansion
ENRICH project launched in 2022 - four-year longitudinal study (2022-2026) analyzing up to 10,000 CT scans from 3,000+ patients across 20 centers in 12 countries, first initiative to integrate AI-powered imaging into ECFS Patient Registry with 54,000 CF patients
Partnerships
Recorded partners
- Erasmus Medical Center Rotterdam
- European Cystic Fibrosis Society (ECFS)
- LungAnalysis Lab at Erasmus MC
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
LungQ AVX (Artery Vein Phenotyping)
Deep characterization of pulmonary arterial and venous blood volume distribution throughout the vascular tree
Software · Cloud SaaSCompany source
LungQ BA (Bronchus-Artery Analysis)
Fully automated quantification of bronchial tree with normalized bronchial dimensions against adjacent arteries
Software · Cloud SaaSCompany source
LungQ MP (Mucus Plugs Analysis)
Fully automatic quantification of airway-occluding mucus plugs with count and volume at global, lobar and segmental levels
Software · Cloud SaaSCompany source
LungQ Navia (Bronchoscopy Pathway Planning)
Automated bronchoscope insertion simulation and path navigation for pre-operative planning and guidance
Software · Cloud SaaSCompany source
LungQ PXT (Perfusion Defect Estimation)
Automated estimation of chronic perfusion defects from CT images by combining parenchymal and vascular data
Software · Cloud SaaSCompany source
LungQ VERA (Ventilation Estimation)
AI-based lung attenuation analysis for detecting hypo-ventilated and hypo-perfused lung volumes in small airways
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective (part 2: special situations/respiratory complications).Respiratory medicine · Aug 1, 2026
Assessing the feasibility of neonatal chest MRI for bronchopulmonary dysplasia using a standard 1.5-Tesla scanner.European radiology · Aug 1, 2026
AI-driven CT quantification of mucus plugs to evaluate the effect of inhaled hypertonic saline in children aged 3-6 years with CF: a randomized controlled trial.The European respiratory journal · Jul 23, 2026
Oxygen-enhanced MRI and multiple breath washout with Short extension reveal cystic fibrosis lung disease progression despite triple modulator therapy.Thorax · Jun 3, 2026
The CFTR potentiator icenticaftor for treatment of bronchiectasis: an international phase 2, double-blind, randomized placebo-controlled trial.American journal of respiratory and critical care medicine · Jun 1, 2026
Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial.Annals of the American Thoracic Society · Jun 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
LungQ 4K250766 · 510k · Oct 2, 2025
LungQ v3.0.0K232412 · 510k · Jan 8, 2024
LungQ SoftwareK173821 · 510k · Jun 5, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Images analyzed
Over 1 million images processed
Scientific publications
100+ peer-reviewed publications
Patient cases
50,000+ patient cases in cohorts
Hospital partnerships
100+ hospitals worldwide
European Cystic Fibrosis Society (ECFS) Patient Registry / Erasmus Medical Center
Standardize quantitative CT metrics in cystic fibrosis population data across Europe by integrating AI-powered imaging outcome analysis into the ECFS Patient Registry containing 54,000 CF patients
Up to 10,000 CT scans analyzed from over 3,000 patients across 20 centers in 12 countries; quantitative analyses confirmed treatment efficacy and identified patient cohort with pronounced baseline abnormalities demonstrating strongest clinical improvement
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Thirona
Recent articles published on Thirona's official website.
Redefining Bronchiectasis Trials Through AI-Powered Image Analysis
Read on ThironaFrom invisible details to powerful insights – LungQ®
Read on ThironaComprehensive assessment of mucus impaction with Artificial Intelligence
Read on ThironaFrom invisible details to powerful insights – LungQ® Mucus Plug Analysis
Read on ThironaStructural Insights in Severe Asthma Paving the Way for More Precise Treatment Stratification
Read on Thirona07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.